bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acquired hypothalamic dysfunction in childhood: ‘what do patients need?’ – an Endo-ERN survey
Authors: van Roessel I M A A , de Graaf J P , Biermasz N R , Charmandari E , van Santen H M 
Published: August 2023

Objective
Hypothalamic dysfunction is a rare condition and can be encountered in patients who have been diagnosed or treated for a suprasellar brain tumor. Due to its rarity, the signs and symptoms of hypothalamic dysfunction may be difficult to recognize, leading to delayed diagnosis of the suprasellar brain tumor or to difficulties in finding the health-care expertise for hypothalamic dysfunction after tumor treatment. To improve the care and outcome of patients with acquired hypothalamic dysfunction, professionals are required to understand the patient’s needs.

Design
A worldwide online survey was distributed from April 2022 to October 2022 to patients with childhood-onset hypothalamic dysfunction (as reported by the patient) following a brain tumor.

Methods
Patients were notified about the survey through patient advocacy groups, the SIOPe craniopharyngioma working group and the Endo-ERN platform.

Results
In total, 353 patients with hypothalamic dysfunction following craniopharyngioma (82.2%), low-grade glioma (3.1%) or a pituitary tumor (8.2%) or caregivers responded to the survey. Sixty-two percent had panhypopituitarism. Obesity (50.7%) and fatigue (48.2%) were considered the most important health problems. Unmet needs were reported for help with diet, exercise and psychosocial issues. Patients’ suggestions for future research include new treatments for hypothalamic obesity and alternative ways for hormone administration.

Conclusions
According to the patient’s perspective, care for acquired hypothalamic dysfunction can be improved if delivered by experts with a holistic view of the patient in a multidisciplinary setting with a focus on quality of life. Future care and research on hypothalamic dysfunction must integrate the patients’ unmet needs.

Significance statement
Patients with hypothalamic dysfunction may experience a variety of symptoms, which are not always adequately recognized or addressed. In previous papers, the perspective of caregivers of children with craniopharyngioma has been reported (Klages et al. 2022, Craven et al. 2022). Now we address the patients’ perspective on acquired hypothalamic dysfunction using an Endo-ERN global survey. According to the patients’ perspective, care can be improved, with needs for improvement in the domains of obesity, fatigue and lifestyle. Research may focus on ways to improve hypothalamic obesity and alternative ways for hormone administration. Ideally, care should be delivered by doctors who have a holistic view of the patient in a multidisciplinary expert team. The results of this study can be used to formulate best practices for clinical care and to design future research proposals.
Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
Authors: Marques Nelma Veronica , Wildemberg Luiz Eduardo Armondi , Gadelha Monica R 
Published: August 2023

Pasireotide long-acting release is effective in achieving biochemical control and reducing tumour volume in patients with acromegaly inadequately controlled by first-line therapy. As part of a long-term, real-world study at our centre, 20 of 50 patients receiving pasireotide benefited from a reduction in pasireotide dose. Pasireotide reduced insulin-like growth factor 1 (IGF1) levels to below the upper limit of the normal range, with some patients responding within 1−3 months of treatment (n = 11) and others after ≥4 months (n = 9). Following pasireotide dose reduction, IGF1 levels showed a mild increase but remained within the normal range after a median of 39 months in the early responders and 17 months in the late responders. Glucose and glycated haemoglobin levels decreased following dose reduction. Identifying patients who may benefit from a reduction in pasireotide dose warrants further research as it may improve the management of pasireotide-associated hyperglycaemia in susceptible patients.

Significance statement
Patients with acromegaly often need medical therapy for extended periods of time, and pasireotide is an effective, long-term treatment option. However, pasireotide may increase blood glucose levels in some patients, such as those with pre-existing diabetes. In this single-centre study, we show that following dose reduction of pasireotide over time, patients with acromegaly maintained their biochemical response (IGF1 < ULN) and had improved glycaemic control. As such, dose reductions may be an effective, personalised treatment approach for managing some patients receiving long-term pasireotide therapy and could allow patients to achieve early and long-term biochemical control while minimising adverse drug effects.
Complete Chloroplast Genome and Comparative Analysis of Entada phaseoloides (Fabaceae)
Authors: Hu Tingting , Chen Si , Xu Pei , Zhou Daoyuan , Zhu Qingsong 
Published: August 2023

Background: Entada phaseoloides (L.) Merr (Fabaceae) is a large woody climber that is found widely in southern China and other tropical and subtropical areas worldwide. The genus Entada contains ~30 species, and E. phaseoloides is most commonly found in China. The E. phaneroneura and E. pervillei are endangered species. Previous studies had focused on medicinal components, transcriptional regulation, and nuclear genomes. The chloroplast genome of Entada has not been reported, and little is known about the phylogenetic relationships within the Entada. In this study, we performed short-read sequencing of E. phaseoloides and assembled and analyzed its chloroplast genome. Methods: Dry specimen leaves of E. phaseoloides were subjected to DNA extraction and sequenced using the Illumina Novoseq platform. The chloroplast genome was assembled using Get Organelle, annotated using CPGAVAS2 and Geneious Prime. Repeat sequences and SSR analysis were performed using the Reputer and MISA programs, respectively. Phylogenetic analyses were performed using IQTREE and MrBayes software. Result: The complete chloroplast genome of E. phaseoloides is 159,963 bp in length and has a quadripartite structure with large single copy of 89,972 bp and a small single copy of 19,309 bp separated by inverted repeats of 25,341 bp. A total of 112 genes in E. phaseoloides comprised 78 protein-coding genes, 30 transfer RNA genes, and 4 ribosomal RNA genes. The distribution of simple sequence repeats and long repeat sequences was determined. We carried out phylogenetic analysis based on homologous protein-coding genes among 21 species derived from Fabaceae. We found that the phylogeny was largely congruent with prior hypotheses about the position of E. phaseoloides in evolutionary branches. The E. phaseoloides has a closer relationship with the Piptadeniastrum africanum.
The Profile and Triggering Factors of Melasma Patients: A Retrospective Study
Authors: Putri Brillian Betrista Viorizka  , Trisniartami Setyaningrum  , Ema Qurnianingsih  , Damayanti  
Published: August 2023

Background: Melasma is a skin pigmentation disorder characterized by brownish hyperpigmented lesions with symmetrical distribution and irregular borders. It becomes a cosmetic problem that causes a negative impact on quality of life and a lack of confidence in patients. The etiology of melasma is not completely understood, but several factors that trigger melasma can be explained. Yet, the profile and triggering factors associated with the prevalence of melasma patients in Surabaya are still unexplored. Purpose: To determine the profile and triggering factors of melasma patients in the Dermatology and Venereology Outpatient Unit of Dr. Soetomo General Academic Hospital Surabaya from January to December 2019. Methods: A retrospective descriptive study using data from medical records with a total sampling technique. Result: In this study, most of the melasma patients were female (97.5%), dominated by the age group 46-55 years (49.4%), and worked as housewives (40.74%). The triggering factors found in patients were sun exposure (96.3%), cosmetics (67.9%), hormonal (49.4%), and family history (22.2%). The physical examinations of melasma lesions showed that they were mostly located in the malar area (72.8%), light brown colored (74.7%), and 2.0 – 4.0 cm in size (54.3%). Wood’s lamp examination showed that most of the lesions had firm and indistinct borders (55.6%). Conclusion: The triggering factors of melasma are multifactorial, but we suspect that sun exposure plays an important role in affecting melasma.
Salvage of a Fractured Proximal Ulnar Osteoarticular Allograft Using a Medial Femoral Condyle Free Flap
Authors: Hoftiezer Yannick Albert J. , Posada Alvarez Carolina , Werenski Joseph O. , Schreuder H.W.B. , Eberlin Kyle R. , Lee Sang-Gil , Lozano-Calderón Santiago A. 
Published: August 2023

Case:
We present the case of a 47-year-old paraplegic woman who underwent resection of an intermediate-grade chondrosarcoma in the proximal ulna, which was initially reconstructed with an osteoarticular allograft. However, after more than 25 years without complications, she sustained an intra-articular fracture of the allograft, which was then successfully treated using a vascularized medial femoral condyle (MFC) flap and anterolateral thigh flap. The patient has subsequently recovered her baseline elbow function, has no pain, and can use her wheelchair without restrictions.

Conclusion:
Free MFC flaps are viable options to salvage osteoarticular allografts that are affected by intra-articular fractures.
Cholesterol modulates type I-type II TGF-β receptor complexes and alters the balance between Smad and Akt signaling in hepatocytes
Authors: Chaudhary Roohi , Goodman Laureen , Wang Sai , Asimakopoulo Anastasia , Weiskirchen Ralf , Dooley Steven , Ehrlich Marcelo , Henis Yoav 
Published: August 2023

Abstract
Cholesterol mediates membrane compartmentalization, affecting signaling via differential distribution of receptors and signaling mediators. While excessive cholesterol and aberrant transforming growth factor-β (TGF-β) signaling characterize multiple liver diseases, their linkage to canonical vs. non-canonical TGF-β signaling remained unclear. Here, we subjected murine hepatocytes to cholesterol depletion (CD) or enrichment (CE), followed by biophysical studies on TGF-β receptor heterocomplex formation, and output to Smad2/3 vs. Akt pathways. Prior to ligand addition, raft-dependent preformed heteromeric receptor complexes were observed. Smad2/3 phosphorylation persisted following CD or CE. CD enhanced phospho-Akt (pAkt) formation by TGF-β or epidermal growth factor (EGF) at 5 min, while reducing it at later time points. Conversely, pAkt formation by TGF-β or EGF was inhibited by CE, suggesting a direct effect on the Akt pathway. The modulation of the balance between TGF-β signaling to Smad2/3 vs. pAkt (by TGF-β or EGF) has potential implications for hepatic diseases and malignancies.
BTHAAT: A Blockchain-based Traceable Hybrid-Anonymity Authentication Technique for Data Middle Platform in Industry 4.0
Authors: Chen Chuqiao , Goyal S. B. , Rajawat Anand Singh , Senthil P. 
Published: August 2023

Abstract
There is currently a growing concern about the preservation of individual privacy, particularly in the context of the increasing usage of Big Data technologies, such as the Data Middle Platform. As such, the question of how to enhance privacy and security has become a primary concern in today's world of Industry 4.0. In this article, we review related literature on the security and privacy challenges of the Data Middle Platform, and explore the use of Blockchain and zero-knowledge proof theories for authentication. We propose an algorithm that combines k-anonymity, homomorphic encryption, blockchain, and zero-knowledge proof for traceable authentication technology, and demonstrate its feasibility in the laboratory. Our experimental results verify the efficacy of the algorithm. As the algorithm is intended for industrial use, we compare and discuss it with existing authentication techniques in the penultimate section. Finally, we conclude our work and highlight directions for future research.
A Cross-Device Ensemble Learning Model for Continuous Cognition Assessment Based on Resting-State EEG
Authors: Lu Bai , Sun Jingnan , Sun Yike , Shen Anruo , Li Yunxia , Gao Xiaorong 
Published: August 2023

Abstract
One critical manifestation of neurological deterioration is the sign of cognitive decline. Causes of cognitive decline include but are not limited to: aging, cerebrovascular disease, Alzheimer's disease, and trauma. Currently, the primary tool used to examine cognitive decline is scale. However, scale examination has drawbacks such as its clinician subjectivity and inconsistent results. This study attempted to use resting-state EEG to construct a cognitive assessment model that is capable of providing a more scientific and robust evaluation on cognition levels. In this study, 75 healthy subjects, 99 patients with Mild Cognitive Impairment (MCI), and 78 patients with dementia were involved. Their resting-state EEG signlas were collected twice, and the recording devices varied. By matching these EEG and traditional scale results, the proposed cognition assessment model was trained based on Adaptive Boosting (AdaBoost) and Support Vector Machines (SVM) methods, mapping subjects' cognitive levels to a 0-100 test score with a mean error of 4.82 (< 5%). This study is the first to establish a continuous evaluation model of cognitive decline on a large sample dataset. Its cross-device usability also suggests universality and robustness of this EEG model, offering a more reliable and affordable way to assess cognitive decline for clinical diagnosis and treatment as well. Furthermore, the interpretability of features involved may further contribute to the early diagnosis and superior treatment evaluation of Alzheimer's disease.
A Methodological Review of Randomised n-of-1 Trials.
Authors: Hawksworth Olivia , Chatters Robin , Julious Steven A , Cook Andrew , Biggs Katie , Solaiman Kiera 
Published: August 2023

Abstract
Background
n-of-1 trials are a type of crossover trial designed to optimise the evaluation of health technologies in individual patients. This trial design may be considered for the evaluation of health technologies in rare conditions where fewer patients are available to take part in research. This review describes the characteristics of randomised n-of-1 trials conducted over the span of a decade, including how the n-of-1 design has been employed to study both rare and non-rare conditions.
Methods
Databases and clinical trials registries were searched for articles including “n-of-1” in the title between 1st January 2011 and 5th May 2021. Randomised n-of-1 trials were selected for inclusion and data were extracted on a range of design, population, and analysis characteristics. Descriptive statistics were produced for all variables.
Results
We identified 52 studies meeting our eligibility criteria, eight of which (15.4%) were conducted in rare conditions. They were conducted in a range of clinical areas with the most common being neuropsychiatric conditions (n = 16, 30.8). The median (interquartile range, IQR) number of participants randomised was 10 (1–20) and 11 trials (21.2%) involved a single patient only. 35 (67.3%) trials evaluated drug interventions and 38 (73.1%) trials were placebo controlled. Trials had a median (IQR) of six (5–8) periods and compared a median (IQR) of two (2–2) health technologies. 41 (78.8%) trials incorporated blinding and 23 (44.3%) had a washout period. 37 trials (71.2%) used patient reported outcome measures (PROMs) to assess the primary outcome. Trials used a range of approaches to analysis and 32 (61.5%) combined data from multiple patients. The characteristics of the n-of-1 trials conducted in rare conditions were generally consistent with those in non-rare conditions.
Conclusions
Our review has summarised the characteristics of randomised n-of-1 trials in rare and non-rare conditions. We hope that it can inform researchers in the design of future n-of-1 studies. Further work is required to provide guidance on specific design considerations and the implementation of these studies.
Registration:
Not applicable.
Migraine Is Associated with the Development of Inflammatory Bowel Disease: A Nationwide, Population-Based Study
Authors: Lee Chan Hyung , Han Kyungdo , Lee Hyun Jung , Yu Hosun , Kim Seulji , Choi Kookhwan , Koh Seong-Joon , Im Jong Pil , Kim Joo Sung 
Published: August 2023

Abstract
Background: It has been reported that migraine is more common in patients with inflammatory bowel disease (IBD) than in general. However, the impact of migraine on the development of IBD has not yet been elucidated. The aim of this study was to determine the association between migraine and the development of IBD.
Methods: This nationwide population-based cohort study was conducted using the Korean National Health Insurance Service (NHIS) database. A total of 10,628,070 people aged 20 years or older who had undergone a national health examination conducted by the NHIS in 2009 were followed up until 2017. The study population was divided into two groups according to the presence or absence of migraine. We analyzed the incidence of newly developed IBD, Crohn’s disease (CD), or ulcerative colitis (UC) during the follow-up period.
Results: The incidence of IBD was significantly higher in patients with migraine (adjusted hazard ratio [aHR] with 95% confidence interval [95%CI] of 1.31 [1.173–1.468], p <0.001), CD (aHR with 95%CI of 1.58 [1.237–2.013], p <0.001) and UC (aHR with 95%CI of 1.26 [1.106–1.424], p<0.001) than in those without migraine. After 5 years of follow-up, those with migraine showed curves implying cumulative incidences of IBD with a steep increase, especially for CD. In subgroup analysis, migraine was associated with the risk of UC in males (aHR, 1.431 vs. 1.117; interaction p = 0.042).
Conclusions: Migraine is significantly associated with the development of IBD. Patients with migraine should be monitored carefully for the development of IBD.
Functional contribution of glutamatergic neurons of medullary reticular nuclei to locomotor recovery after spinal cord injury
Authors: Bretzner Frederic , Lemieux Maxime , Karimi Narges 
Published: August 2023

Abstract
Spinal cord injury (SCI) disrupts the descending drive from the brain and causes a range of deficits. We have investigated the functional plasticity of the glutamatergic reticulospinal drive of the medullary reticular formation (MRF) after a lateral thoracic hemisection in mice. The excitatory descending drive was impaired after SCI, independently of its origin. The direction of functional plasticity was anti-correlated with its pre-injury efficacy. Stimulation of sites in the most dorsal MRF decelerated or stopped locomotion, whereas the most ventral sites increased speed. The ability to steer was preserved with modest impairment. Activating the descending MRF drive improved stepping ability of chronically impaired SCI mice and its conditioning improved recovery of skilled locomotion. These results highlight the resilience and capacity for reorganization of the glutamatergic reticulospinal command after SCI, along with its suitability as a therapeutical target to promote functional recovery.
The effects of anti-ageing mono- and bipolar radiofrequency treatment on the self-esteem of pre-menopausal and menopausal women
Authors: Skalska-Stochaj Agata , Grochowalska Alina , Hojan-Jezierska Dorota , Kubisz Leszek 
Published: August 2023

Abstract
The study attempted to address the issue whether undergoing procedures radiofrequency results in positive changes in the assessment of their own appearance in women between the ages of 40 and 69. The aim of the survey was to determine whether the procedure, mono- and bipolar radiofrequency, applied to the skin of the face, can increase women's self-esteem. A subjective evaluation was performed to determine the actual persistence of a 4-month monopolar (RFM) and bipolar (RFB) radiofrequency treatment in the selected age groups. The study included 90 women reporting good general health, with a clinically healthy skin. The study population was divided into two groups, and the allocation to groups was randomized. The RFM method involved a group of 45 women receiving monopolar radiofrequency therapy, in which the following age groups were distinguished (15 women): I 40–49 years of age, II 50–59 y.o.a., III 60–69 y.o.a.. The RFB method comprised a group of 45 women who were subject to bipolar radiofrequency, and the participants were divided into the following age groups (15 women): I 40–49 years of age, II 50–59 y.o.a., III 60–69 y.o.a. The response rate was 100%. The study was aimed at indicating an important aspect of women's self-esteem.
Racial and Survival Disparities in Inflammatory Breast Cancer (IBC) and non-IBC: A Population-Based Study Focused on Native Hawaiians and Other Pacific Islanders
Authors: Yoshikawa Gene , Miyazaki Kyle , Acoba Jared , Fujii Takeo 
Published: August 2023

Abstract
Background
Breast cancer has the highest incidence among all malignancies and is the second leading cause of cancer death among women in the United States. It is well known that race is an independent predictor of breast cancer mortality and advanced stage at diagnosis. Inflammatory breast cancer (IBC) is the most aggressive type of breast cancer and has distinct clinical and biological features. Previous studies have shown that Blacks have a higher incidence of IBC than Whites. However, the proportion of IBC and the role of race on prognosis in Native Hawaiian and other Pacific Islander (NH/PI) populations with breast cancer are poorly understood. In this study, we aimed to examine the proportion of IBC to non-IBC in NH/PIs and to identify the clinicopathological, biological, and socioeconomic factors associated with the overall survival of NH/PIs compared to other races.
Methods
Utilizing a comprehensive cancer registry from the largest hospital in Hawaii, newly diagnosed primary invasive breast cancer patients diagnosed between 2000 and 2018 were identified. Univariate and multivariate Cox proportional hazards models were used to test the association between race and clinical outcomes. Variables with P-values <0.05 in the univariate analysis and race (variable of interest) were included in a multivariate analysis.
Results
The cohort included 3691 patients, 60 of whom had IBC. NH/PI race had the highest proportion of IBC compared to other races (3.44%) but was not found to be an independent poor prognostic factor in IBC (HR 1.17 [95%CI 0.26-5.22]). Conversely, NH/PI race was associated with worse survival outcomes in patients with non-IBC (HR 1.65 [95%CI, 1.14-2.39]) along with other factors such as lack of insurance, underinsured status, triple-negative breast cancer (TNBC) subtype, age, and advanced clinical stage.
Conclusions
The findings of this study highlight that NH/PIs had higher rates of IBC and inferior survival in non-IBC compared to other races but not in IBC. It is essential to disaggregate NH/PI race from Asians in future population-based research studies. Further research is needed to understand the factors contributing to higher rates of IBC and poor survival outcomes in NH/PIs with non-IBC as well as targeted interventions to improve breast cancer outcomes in this population to ultimately help improve survival rates and reduce health inequities in NH/PIs with breast cancer.